Showing 2711-2720 of 3858 results for "".
- Prurigo Nodularis Diagnosis Centers on Clinical Recognition, Not Biopsy, Dr. Elmariah Sayshttps://practicaldermatology.com/news/prurigo-nodularis-diagnosis-centers-on-clinical-recognition-not-biopsy-dr-elmariah-says/2486417/A pragmatic, clinically driven approach is necessary for diagnosing prurigo nodularis (PN), and a biopsy is often unnecessary when key features are present, according to a talk by Sarina Elmariah, MD, FAAD, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. “It is these thre
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://practicaldermatology.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Case Study: Non-Invasive Combo Therapy Resolves Nodular BCChttps://practicaldermatology.com/news/case-study-non-invasive-combo-therapy-resolves-nodular-bcc/2476081/A combination of cryotherapy, 5-fluorouracil, and imiquimod achieved clinical resolution of a large nodular basal cell carcinoma (nBCC) in the inguinal region, according to a recent case report in the Journal of Clinical and Aest
- Elevated IFN Signatures Seen in Nonlesional Skin of Cutaneous Lupus Erythematosus Patientshttps://practicaldermatology.com/news/elevated-ifn-signatures-seen-in-nonlesional-skin-of-cle-patients/2475210/Patients with systemic lupus erythematosus (SLE) and a history of cutaneous lupus erythematosus (CLE) showed elevated interferon-stimulated gene (ISG) expression in blood and nonlesional skin, according to a new study. The si
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).